Stifel analyst Paul Matteis reiterated a Buy rating on Eliem Therapeutics Inc. (NASDAQ: ELYM), following a recent investor event with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE